Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Lieberman

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
American Journal of Therapeutics|March 16, 2005
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapyNushin F Todd, Ronald Lieberman, James L Gulley, et al.
American Journal of Therapeutics|January 29, 2008
Lycopene in cancer prevention and treatmentSoley Seren, Ronald Lieberman, Ulas D Bayraktar, et al.
American Journal of Therapeutics|January 24, 2014
Cardiovascular safety monitoring during oncology drug development and therapyJ Rick Turner, Gopi Krishna Panicker, Dilip R Karnad, et al.
Molecular Cancer Therapeutics|August 8, 2006
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis modelYusheng Jin, Kenneth K Iwata, Arie Belldegrun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasiaVered Stearns, Andrew Coop, Baljit Singh, et al.
Clinical Lung Cancer|December 3, 2014
An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancerCornelius F Waller, Ihor Vynnychenko, Igor Bondarenko, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2008
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trialAnne R Simoneau, Eugene W Gerner, Ray Nagle, et al.
American Journal of Therapeutics|July 22, 2006
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trialSteven R Alberts, Paul J Novotny, Jeff A Sloan, et al.
The Journal of Urology|July 12, 2005
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancerPhilip M Arlen, James L Gulley, Nushin Todd, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 10, 2006
Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasiaJames R Marshall, Wael Sakr, David Wood, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
American Journal of Therapeutics|March 16, 2005
Prolonged response to nilutamide in a patient with stage D0.5 prostate cancer who previously failed androgen deprivation therapyNushin F Todd, Ronald Lieberman, James L Gulley, et al.
American Journal of Therapeutics|January 29, 2008
Lycopene in cancer prevention and treatmentSoley Seren, Ronald Lieberman, Ulas D Bayraktar, et al.
American Journal of Therapeutics|January 24, 2014
Cardiovascular safety monitoring during oncology drug development and therapyJ Rick Turner, Gopi Krishna Panicker, Dilip R Karnad, et al.
Molecular Cancer Therapeutics|August 8, 2006
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis modelYusheng Jin, Kenneth K Iwata, Arie Belldegrun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasiaVered Stearns, Andrew Coop, Baljit Singh, et al.
Clinical Lung Cancer|December 3, 2014
An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancerCornelius F Waller, Ihor Vynnychenko, Igor Bondarenko, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 13, 2008
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trialAnne R Simoneau, Eugene W Gerner, Ray Nagle, et al.
American Journal of Therapeutics|July 22, 2006
Flutamide in men with prostatic intraepithelial neoplasia: a randomized, placebo-controlled chemoprevention trialSteven R Alberts, Paul J Novotny, Jeff A Sloan, et al.
The Journal of Urology|July 12, 2005
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancerPhilip M Arlen, James L Gulley, Nushin Todd, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 10, 2006
Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasiaJames R Marshall, Wael Sakr, David Wood, et al.
Pageof 3